Overview of the drug development pipeline for candidiasis
Candidiasis can be defined as a fungal infection caused by yeasts that belong to the genus Candida. Imbalance in normal flora in the mouth and throat make a suitable environment for the fungus to multiply, which can lead to candidiasis. According to the Centers for Disease Control and Prevention (CDC), around 75% of women has at least one episode of vulvovaginal candidiasis (VVC) and 40%-45% had at least two or more episodes of VVC globally. Monotherapy is emerging as the most effective approach for the treatment of candidiasis.
According to this pipeline analysis report, most of the drug molecules in the pipeline are being developed for VVC. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.
Companies covered
This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of candidiasis. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug molecules discontinued by companies.
Some of the companies covered in this pipeline analysis report are:
- Amplyx
- Bionex Pharmaceuticals
- Biosergen
Therapeutic assessment of the drug development pipeline for candidiasis by route of administration
- Oral
- Topical
- IV
- Intravaginal
- Intramuscular
- Unknown
The oral route of administration (ROA) involves the application of the drug directly into the mouth cavity and in the topical technique, the molecules are applied to the body surface such as skin or mucous membrane, which will have a more direct effect on the target cells.
Therapeutic assessment of the drug development pipeline for candidiasis by therapy
- Monotherapy
- Unknown
According to this pipeline analysis report, most of the molecules that are currently in the drug pipeline for candidiasis are being developed as monotherapy drugs and most of these molecules are in the pre-clinical stage of development.
Key questions answered in the report include
- What are the gene therapy molecules in the various development stages for candidiasis?
- What are the companies that are currently involved in the development of drug molecules for candidiasis?
- Insight into discontinued/inactive molecules with appropriate reasoning?
- What are the major regulatory authorities approving drugs in various regions?
- Detailed profiling of each active molecule
Technavio also offers customization on reports based on specific client requirement.